Adaptive Biotechnologies Corporation
ADPT
$7.10
-$0.31-4.18%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 3.66% | 22.46% | -11.72% | 11.23% | -17.05% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.66% | 22.46% | -11.72% | 11.23% | -17.05% |
| Cost of Revenue | 16.24% | -14.72% | 0.20% | -5.82% | -211.46% |
| Gross Profit | -7.05% | 156.28% | -22.69% | 52.89% | 1,241.19% |
| SG&A Expenses | -7.04% | -6.80% | -17.25% | -2.84% | -7.61% |
| Depreciation & Amortization | -0.23% | 0.00% | 0.24% | 0.95% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.08% | -11.04% | -13.89% | -4.43% | -3.14% |
| Operating Income | 25.86% | 35.96% | 16.11% | 14.74% | -16.47% |
| Income Before Tax | 51.46% | 36.22% | 3.27% | 17.62% | -72.94% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 51.46% | 36.22% | 3.27% | 17.62% | -72.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -3.85% | 0.00% | 2,500.00% | 2,500.00% | -36.59% |
| Net Income | 51.48% | 36.24% | 3.32% | 17.66% | -73.05% |
| EBIT | 25.86% | 35.96% | 16.11% | 14.74% | -16.47% |
| EBITDA | 26.98% | 37.95% | 16.73% | 15.88% | -18.72% |
| EPS Basic | 52.40% | 37.46% | 5.29% | 18.95% | -70.84% |
| Normalized Basic EPS | 26.57% | 37.48% | 20.06% | 16.80% | -12.56% |
| EPS Diluted | 52.40% | 37.46% | 5.29% | 18.95% | -70.84% |
| Normalized Diluted EPS | 26.57% | 37.48% | 20.06% | 16.80% | -12.56% |
| Average Basic Shares Outstanding | 1.92% | 1.94% | 2.09% | 1.59% | 1.29% |
| Average Diluted Shares Outstanding | 1.92% | 1.94% | 2.09% | 1.59% | 1.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
